Back to Search Start Over

Identification and functional characterization of CD8+ T regulatory cells in type 1 diabetes patients.

Authors :
Pellegrino, Marsha
Crinò, Antonino
Rosado, Manuela M.
Fierabracci, Alessandra
Source :
PLoS ONE; 1/16/2019, Vol. 14 Issue 1, p1-20, 20p
Publication Year :
2019

Abstract

Type 1 diabetes is an autoimmune disease where autoreactive T lymphocytes destroy pancreatic beta cells. We previously reported a defect in CD4<superscript>+</superscript> Tregs cell proliferation and reduced CD4<superscript>+</superscript> Tregs PD-1 expression in patients. Another ‘memory-like’ regulatory subset, CD8<superscript>+</superscript> Tregs, evaluated as CD8<superscript>+</superscript>CD25<superscript>+</superscript>FOXP3<superscript>+</superscript>, has recently raised interest for their effective suppressive activity. Different CD8<superscript>+</superscript> T cell populations, their proliferation capacity and expression of PD-1 molecule were evaluated by flow-cytometer analysis in newly diagnosed, long-term Type 1 diabetes patients compared to healthy normal donors. Under basal conditions, CD8<superscript>+</superscript> Tregs and CD8<superscript>+</superscript> Teffs were seemingly represented among study groups while there was evidence of diminished expression of PD-1 in Teff subsets of long-term patients. After 3 days of PMA/ionomycin stimulation, patients CD8<superscript>+</superscript> Tregs showed decreased percentage in respect to control group. CD8<superscript>+</superscript> Teffs were instead increased in long-term diabetics versus controls. PD-1<superscript>+</superscript>CD8<superscript>+</superscript> Tregs were represented at a much lower percentage in long-term diabetic patients, in respect to controls. Importantly, patients CD8<superscript>+</superscript> Tregs and CD8<superscript>+</superscript> Teffs presented a significant proliferation defect in respect to the control group. In conclusion, our study indicates that a defect of CD8<superscript>+</superscript> Tregs is observed in diabetics. This subset could thus represent a novel target of immunotherapy in patients. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
19326203
Volume :
14
Issue :
1
Database :
Complementary Index
Journal :
PLoS ONE
Publication Type :
Academic Journal
Accession number :
134132761
Full Text :
https://doi.org/10.1371/journal.pone.0210839